Katrina Warner

Katrina Warner

Auto-generated profile, based on publicly available information

Katrina Warner

Biological and Biomedical Sciences Program, Harvard University, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
GFGlenna Wink Foight
Glenna Wink Foight
ZWZhizhi Wang
Zhizhi Wang
CWCindy T. Wei
Cindy T. Wei
PGPer Jr Greisen
Per Jr Greisen
KWKatrina M. Warner
Katrina M. Warner
DMDustin J. Maly
Dustin J. Maly

20 April 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SBSong Yi Bae
Song Yi Bae
NGNing Guan
Ning Guan
RYRui Yan
Rui Yan
KWKatrina Warner
Katrina Warner
STScott D. Taylor
Scott D. Taylor
AMAaron S. Meyer
Aaron S. Meyer
Cancer cell sensitivity or resistance is almost universally quantified through a direct or surrogate measure of cell number. However, compound responses can occur through many distinct phenotypic outcomes, including changes in cell growth, apoptosis, and non-apoptotic cell death. These outcomes have divergent effects on the tumor microenvironment, immune response, and resistance mechanisms. Here, we show that quantifying cell viability alone is insufficient to distinguish between these compound responses. Using an alternative assay and drug-response analysis amenable to high-throughput measurement, we find that compounds with identical viability outcomes can have very different effects on cell growth and death. Moreover, additive compound pairs with distinct growth/death effects can appear synergistic when only assessed by viability. Overall, these results demonstrate an approach to incorporating measurements of cell death when characterizing a pharmacologic response.

4 December 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSong Yi Bae
Song Yi Bae
NGNing Guan
Ning Guan
RYRui Yan
Rui Yan
KWKatrina Warner
Katrina Warner
AMAaron Samuel Meyer
Aaron Samuel Meyer
Cancer cell sensitivity or resistance is almost universally quantified through a direct or surrogate measure of cell number. However, compound responses can occur through many distinct phenotypic outcomes including changes in cell growth, apoptosis, and non-apoptotic cell death. These outcomes have distinct effects on the tumor microenvironment, immune responses, and resistance mechanisms. Here, we show that quantifying cell viability alone is insufficient to distinguish between these compound responses. Using an alternative assay and drug response analysis amenable to high-throughput measurement, we find that compounds with identical viability outcomes can have very different effects on cell growth and death. Moreover, compound pairs with additive cell growth and death effects can appear synergistic when only assessed by viability. Overall, these results demonstrate an approach to incorporating measurements of cell death when characterizing a pharmacologic response. Summary Points: Measurements of solely live cell numbers mask important differences in compound effects. Additive effects on growth and death rates can appear synergistic when analyzed solely via live cell number. Automated imaging can provide reasonable throughput to analyze cell response in terms of cell growth and death, and endpoint analysis is similarly informative.